Pilot Study of Irreversible Electroporation (IRE) to Treat Metastatic Liver Cancer & Cholangiocarcinoma

Inclusion Criteria: * older than 18 years, * male or female, * diagnosis of secondary liver cancer or cholangiocarcinoma based on positive biopsy or noninvasive criteria, * presence of at least one lesion untreatable by surgical resection or ablation for microwave or radio frequency, * the target nodule must have a diameter of ≤ 5 cm * ECOG score(Eastern Cooperative Oncology Group) 0, * ASA score (American Society of Anesthesiologists) ≤ 3, * prothrombin time ratio \>50% * platelet count \>50x10\^9/l, * patient's ability to discontinue anticoagulant and antiplatelet therapy for seven days before and seven days after surgery with NanoKnife™, * ability to understand and willingness to sign the written informed consent form (ICF), * life expectancy of at least 3 months. Exclusion Criteria: * presence of more than 5 liver lesions, * previous treatment of the target nodule, * patient received systemic chemotherapy within 30 days of treatment with the IRE NanoKnife™, * heart failure, coronary artery disease or arrhythmia in progress, active implantable devices (eg pacemaker), * pregnant women or women of childbearing potential not using an acceptable method of contraception, * patient undergoing treatment with an investigational drug within 30 days of treatment with the IRE NanoKnife™, * in the opinion of the researcher, anyone who can not follow the calendar of visits and assessments of the Protocol.